Related Experiment Video
Updated: Jul 19, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
New Paradigms for CKD Management in Patients With T2D
Learning Objectives:
At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. Become familiar with the novel nonsteroidal mineralocorticoid receptor antagonist finerenone and its role in the treatment of patients with T2D and CKD.
Insights
Patients with type 2 diabetes (T2D) face significant kidney disease risks. This activity covers screening, evidence-based therapies, and the role of finerenone in managing chronic kidney disease (CKD) in T2D.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes (T2D) is a leading cause of chronic kidney disease (CKD).
- Diabetic kidney disease (DKD) significantly increases morbidity and mortality.
- Early detection and intervention are crucial for managing DKD progression.
Purpose of the Study:
- To educate healthcare professionals on identifying CKD risks in T2D patients.
- To outline appropriate screening strategies for CKD in T2D.
- To review evidence-based treatments for slowing DKD progression, including novel agents like finerenone.
Main Methods:
- Review of current clinical guidelines and landmark trials.
- Discussion of diagnostic criteria and screening protocols for CKD in T2D.
- Analysis of the mechanism of action and clinical data for finerenone.
Main Results:
- Understanding the multifactorial risks and consequences of kidney disease in T2D.
- Proficiency in screening for CKD using established biomarkers and diagnostic tools.
- Knowledge of therapeutic strategies to mitigate DKD progression.
Conclusions:
- Effective management of T2D and CKD requires a comprehensive approach.
- Finerenone represents a significant advancement in treating T2D with CKD.
- Continuous medical education is vital for optimizing patient outcomes in DKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction

